ADITXT INC.

NASDAQ: ADTX (Aditxt, Inc.)

Kemas kini terakhir: 06 Apr, 6:00PM

4.73

-0.85 (-15.23%)

  • 1H -15.23%
  • 5H 184.94%
  • 1B 105.65%
  • 6B -95.27%
  • Tahun Ke Tarikh -90.30%
  • 1T -99.98%
  • 5T -100.00%
Penutupan Terdahulu 5.58
Buka 5.47
Jumlah Dagangan 112,469
Purata Dagangan (3B) 2,973,946
Modal Pasaran 4,877,103
Harga / Jualan (P/S) 2.08
Harga / Buku (P/B) 0.470
Julat 52 Minggu
4.11 (-13%) — 34,180.00 (722521%)
Tarikh Pendapatan 19 May 2025 - 23 May 2025
Margin Operasi (TTM) -177,985.30%
EPS Cair (TTM) -311.18
Pertumbuhan Hasil Suku Tahunan (YOY) -96.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 83.52%
Nisbah Semasa (MRQ) 0.090
Aliran Tunai Operasi (OCF TTM) -16.76 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -4.33 M
Pulangan Atas Aset (ROA TTM) -45.40%
Pulangan Atas Ekuiti (ROE TTM) -287.84%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Aditxt, Inc. Bercampur Bercampur

AISkor Stockmoo

0.1
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 5.0
Osilator Teknikal -0.5
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ADTX 5 M - - 0.470
ARWR 2 B - - 33.97
SPRY 1 B - - 5.32
GHRS 686 M - - 2.25
VIR 622 M - - 0.610
REPL 560 M - - 1.12

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Institusi 0.03%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
19 May 2025 Pengumuman Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
02 May 2025 Pengumuman Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
17 Apr 2025 Pengumuman DELETED: Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™
16 Apr 2025 Pengumuman Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
14 Apr 2025 Pengumuman Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
11 Apr 2025 Pengumuman Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
09 Apr 2025 Pengumuman Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
02 Apr 2025 Pengumuman Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
02 Apr 2025 Pengumuman Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
28 Mar 2025 Pengumuman Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
24 Mar 2025 Pengumuman Evofem Reports Fourth Consecutive Year of Net Sales Growth
24 Mar 2025 Pengumuman Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
18 Mar 2025 Pengumuman Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
17 Mar 2025 Pengumuman Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025
12 Mar 2025 Pengumuman Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025
06 Mar 2025 Pengumuman Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.
Papar semua
2.272.272.012.011.761.761.511.511.251.25May 14May 14May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-0.500-0.500-1.000-1.000-1.500-1.500-2.000-2.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda